Minnesota Headlines

Immune thrombocytopenia Epidemiology Insights, Analysis, and Forecasted Trends – 2017-30

 Breaking News
  • No posts were found

Immune thrombocytopenia Epidemiology Insights, Analysis, and Forecasted Trends – 2017-30

May 27
02:16 2020
Immune thrombocytopenia Epidemiology Insights, Analysis, and Forecasted Trends -  2017-30

Immune thrombocytopenia Epidemiology | ITP Epidemiology
Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.
DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.

DelveInsight’s ‘Immune Thrombocytopenia (ITP) – Epidemiology Forecast–2030’ report delivers an in-depth understanding of the ITP, historical and forecasted epidemiology as well as the ITP trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Disease Overview

Immune thrombocytopenia (ITP), previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its own platelets and destroys them too quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. Many of the symptoms of immune thrombocytopenia, stem from a low platelet count leading to excessive bleeding.

Click to read more.

Immune Thrombocytopenia (ITP) Epidemiology 

DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.

Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of ITP, Total Diagnosed Prevalent Population of ITP, and Gender-specific Diagnosed Prevalent Population of ITP scenario of ITP in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Request for sample pages.

Immune Thrombocytopenia (ITP) Detailed Epidemiology Segmentation

  • Assessments as per DelveInsight’s analysts show that the majority of cases of ITP are females as compared to males. There was a total of 32,364 female and 20,998 male diagnosed cases of ITP in 2017 in the United States.
  • DelveInsight’s estimations suggest that the total prevalent population ITP in the seven major markets was approximately 180,498 in 2017.
  • The total diagnosed prevalent cases in the 7MM was estimated to be approximately 147,174 in 2017.
  • In 2017, there were around 63,725 prevalent cases and approximately 53,362 diagnosed prevalent cases of ITP in the United States. Out of the total diagnosed cases, approximately 49,640 cases account for adult ITP and approximately 3,723 cases were diagnosed prevalence population in children in 2017 in the United States.
  • Japan had 27,005 prevalent cases of ITP in 2017.
  • Among the European countries, the United Kingdom had the highest prevalent population of ITP with approximately 26,274 cases, followed by Italy which had a prevalent population of approximately 18,604 in 2017. On the other hand, Spain had the lowest prevalent population of approximately 12,207 cases in 2017.

 

Visit to know more about the report.

 

Table of contents

1. Report Introduction

2. Immune thrombocytopenia (ITP) 

3. Immune thrombocytopenia (ITP) Current Treatment Patterns

4. Immune thrombocytopenia (ITP) – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Immune thrombocytopenia (ITP) Late Stage Products (Phase-III)

7. Immune thrombocytopenia (ITP) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Immune thrombocytopenia (ITP) Discontinued Products

13. Immune thrombocytopenia (ITP) Product Profiles

14. Immune thrombocytopenia (ITP) Key Companies

15. Immune thrombocytopenia (ITP) Key Products

16. Dormant and Discontinued Products

17. Immune thrombocytopenia (ITP) Unmet Needs

18. Immune thrombocytopenia (ITP) Future Perspectives

19. Immune thrombocytopenia (ITP) Analyst Review  

20. Appendix

21. Report Methodology

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/